Full-Time

Tumor Portfolio Director

GI Cancers and Emerging Portfolio, OBU Global Medical Affairs

Posted on 4/15/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$144k - $216k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program

Senior

Gaithersburg, MD, USA

The position requires a minimum of three days per week in the office, indicating a hybrid work model.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in scientific field or life science.
  • Minimum of 7 years of experience in pharmaceutical industry or regulated medical products industry.
  • Minimum of 3 years of experience in Medical Affairs, Commercial, and R&D organizations (Global, regional, or local).
  • Minimum of 3 years of demonstrated project management experience in a matrix organization.
  • Experience working with senior stakeholders.
  • Experience proactively and confidently leading and guiding matrix teams including some team members who are more senior and/or are from various functions and parts of the organization.
  • Comprehensive understanding of the development and commercialization of pharmaceutical products.
  • Experience of successfully influencing cross-functionally, cross-culturally, and cross-brands.
  • Experience of effectively working in a multi-cultural, matrixed environment.
  • Experience working in a global setting, managing stakeholders within different time zones.
  • Experience preparing and/or delivering presentations to executive leadership.
Responsibilities
  • Partner with the GI and Emerging Portfolio Franchise Head as a thought partner to develop and execute the portfolio tumor strategy collaboratively across indications and optimize global and local interfaces for execution.
  • Facilitate overall budget and strategic workforce planning across the global franchise team, including forecasting, phasing, and prioritization across the business planning cycle.
  • Drive strategic planning for key franchise team deliverables, including development of Medical Plans, Integrated Evidence Plans, High Impact Study Proposals, launch plans, Congress plans, and Scientific exchange plans.
  • Facilitate Externally Sponsored Research Review Committee meetings for timely review and decisions on proposals within AZ.
  • Create and maintain dashboard for portfolio progress against scorecard objectives.
  • Manage, train, and develop a small team of Indication Project Managers (IPMs), assigning specific project responsibilities and creating a high-performing team by building trust and providing mentorship.
  • Partner with IPMs to drive efficient functioning of the Medical Implementation Teams (MITs) and ensure connectivity with Integrated Business Teams (IBTs).
  • Accountable for implementing medical standards to ensure compliant functioning of the organization.
  • Plan and lead key franchise-level meetings and workshops, in partnership with the franchise head and franchise leadership team.
  • Identify decisions and track actions to monitor team progress in meetings.
  • Coordinate senior leadership requests for presentations on key topics/initiatives.
  • Drive continuous improvement on ways of working to share best practices to streamline and simplify business processes.
  • Lead key workstreams that drive improvements and change across the broader OBU or GMA organizations.
Desired Qualifications
  • MBA, Ph.D., or PharmD desired.
  • People management experience strongly preferred but not required.
  • Experience managing, mentoring, and developing project managers strongly preferred but not required.
  • Graduate level degree in sciences or business degree preferred.
  • Six Sigma Medical/Process Excellence and/or Project Management/PMP/FPX certification is a plus but not required.
  • Depth of understanding of medical, scientific, and/or commercial pharmaceutical marketplace of Oncology is a plus.
  • Strong leadership, organizational, and communication skills
  • Skilled in change management including process development and implementation, people development, organizational effectiveness, and communication
  • Able to deliver high quality work outputs despite ambiguity or ever-changing environment
  • Delivery focus with an ability to oversee and manage multiple project deliverables in very short timelines
  • Interpersonal skills with an ability to display a variety of leadership styles dependent upon the situation
  • Evidence of the ability to pull together diverse teams over whom they have no line management responsibility in a matrix environment (i.e. Ability to influence and drive for results)
  • Demonstrated knowledge and very wide understanding of global business context
  • An excellent communicator; evidence of strong independence and innovative seeker of strategic solutions; forward looking
  • Strong leadership attributes to clarify strategic direction, generate commitment, balance short and long-term needs, resolve differences constructively, and reinforce expectations

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships, such as their Open Innovation program, which allows collaboration with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through innovation and collaboration.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery enhances AstraZeneca's R&D efficiency.
  • Real-world evidence streamlines AstraZeneca's drug approval processes.
  • Personalized medicine aligns with AstraZeneca's focus on precision therapies.

What critics are saying

  • Class-action lawsuit over Soliris could lead to financial penalties.
  • AI tool for breast cancer screening may face effectiveness challenges.
  • Foreign investment regulations in France may impact Dunkirk expansion.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapy areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery through shared resources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
Apr 22nd, 2025
Enhertu Combination Improved Pfs In 1L Her2+ Mbc

Enhertu combination improved PFS in 1L HER2+ mBC

Life Sciences IP Review
Apr 17th, 2025
AstraZeneca unit faces class-action suit over alleged Soliris monopoly

AstraZeneca unit faces class-action suit over alleged soliris monopoly.

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

INACTIVE